Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
Carlos A. Castañeda(Instituto Nacional de Enfermedades Neoplásicas), Tatiana Vidaurre(The University of Texas MD Anderson Cancer Center), Carolina Belmar-López(Instituto Nacional de Enfermedades Neoplásicas), Elizabeth A. Mittendorf(Beth Israel Deaconess Medical Center), Miluska Castillo(Instituto Nacional de Enfermedades Neoplásicas), Henry Gómez(National Cancer Center), Manuel Cotrina(The University of Texas MD Anderson Cancer Center), Teresa Nunez(The University of Texas MD Anderson Cancer Center), Yun Wu(University at Buffalo, State University of New York), Sandro Casavilca‐Zambrano(Institute for Anthropological Research), Gabriela Calderón(The University of Texas MD Anderson Cancer Center), Julio E. Abugattas(City of Hope), Ketty Dolores-Cerna(The University of Texas MD Anderson Cancer Center), Carlos Barrionuevo(National University of San Marcos), Patricia Arboleda(The University of Texas MD Anderson Cancer Center), Miguel De la Cruz(The University of Texas MD Anderson Cancer Center), Jorge Dunstan(The University of Texas MD Anderson Cancer Center)
Cited by 60
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|988
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751